Medicamen Biotech
Medicamen Biotech Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Medicamen Biotech
Start SIPMedicamen Biotech Investment Rating
-
Master Rating:
-
Medicamen Biotech has an operating revenue of Rs. 124.96 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 16% is great, ROE of 10% is good. The company has a reasonable debt to equity of 3%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 58 which is a POOR score indicating inconsistency in earnings, a RS Rating of 33 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 34 | 34 | 33 | 23 |
| Operating Expenses Qtr Cr | 28 | 28 | 27 | 18 |
| Operating Profit Qtr Cr | 6 | 6 | 6 | 5 |
| Depreciation Qtr Cr | 2 | 2 | 2 | 2 |
| Interest Qtr Cr | 1 | 1 | 1 | 1 |
| Tax Qtr Cr | 0 | 1 | 1 | 0 |
| Net Profit Qtr Cr | 4 | 4 | 4 | 3 |
Medicamen Biotech Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 9
- Bearish Moving Average
- ___
- 7
- 20 Day
- 641.93
- 50 Day
- 688.38
- 100 Day
- 743.51
- 200 Day
- 776.18
- 20 Day
- 638.05
- 50 Day
- 693.09
- 100 Day
- 769.96
- 200 Day
- 813.41
Medicamen Biotech Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 642.79 |
| Second Resistance | 663.07 |
| Third Resistance | 675.14 |
| RSI | 48.6 |
| MFI | 66.84 |
| MACD Single Line | -21.62 |
| MACD | -15.63 |
| Support | |
|---|---|
| First Resistance | 610.44 |
| Second Resistance | 598.37 |
| Third Resistance | 578.09 |
Medicamen Biotech Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 26,051 | 1,687,844 | 64.79 |
| Week | 24,285 | 1,805,818 | 74.36 |
| 1 Month | 18,585 | 1,237,790 | 66.6 |
| 6 Month | 12,455 | 767,880 | 61.65 |
Medicamen Biotech Result Highlights
Medicamen Biotech Synopsis
NSE-Medical-Generic Drugs
Medicamen Biotec is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 115.45 Cr. and Equity Capital is Rs. 12.22 Cr. for the Year ended 31/03/2022. Medicamen Biotech Ltd. is a Public Limited Listed company incorporated on 22/12/1993 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1993PLC056594 and registration number is 056594.| Market Cap | 818 |
| Sales | 123 |
| Shares in Float | 0.72 |
| No of funds | 6 |
| Yield | 0.15 |
| Book Value | 5.33 |
| U/D Vol ratio | 1.2 |
| LTDebt / Equity | 3 |
| Alpha | 0.07 |
| Beta | 1.04 |
Medicamen Biotech
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 43.21% | 43.21% | 43.6% | |
| Mutual Funds | ||||
| Foreign Portfolio Investors | 0.17% | 1.83% | 0.35% | |
| Individual Investors | 31.36% | 30.94% | 35.02% | |
| Others | 25.26% | 24.02% | 21.03% |
Medicamen Biotech Management
| Name | Designation |
|---|---|
| Mr. Rahul Bishnoi | Chairman |
| Dr. Vimal Kumar Shrawat | Non Executive Director |
| Mr. Sanjay Bansal | Non Executive Director |
| Mr. Suresh Kumar Singh | Non Executive Director |
| Mr. Ashwani Kumar Sharma | Non Executive Director |
| Ms. Sangeeta Bishnoi | Independent Director |
| Dr. Ravi Kumar Bansal | Independent Director |
| Mr. Harish Pande | Independent Director |
| Mr. Arun Kumar | Independent Director |
| Ms. Sumita Dwivedi | Independent Director |
Medicamen Biotech Forecast
Price Estimates
Medicamen Biotech FAQs
What is Share Price of Medicamen Biotech ?
Medicamen Biotech share price is ₹658 As on 30 March, 2023 | 07:31
What is the Market Cap of Medicamen Biotech ?
The Market Cap of Medicamen Biotech is ₹832.4 Cr As on 30 March, 2023 | 07:31
What is the P/E ratio of Medicamen Biotech ?
The P/E ratio of Medicamen Biotech is 60.7 As on 30 March, 2023 | 07:31
What is the PB ratio of Medicamen Biotech ?
The PB ratio of Medicamen Biotech is 5.7 As on 30 March, 2023 | 07:31